Olayinka Adejoke Kotila

Dr. Olayinka Adejoke Kotila


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2019 in BMC Research Notes
Verified
Journal Article
Open access
PDF file
MOMojisola Morenike Oluwasanu
Mojisola Morenike Oluwasanu
NANtekim Atara
Ntekim Atara
WBWilliams Balogun
Williams Balogun
OAOlutosin Awolude
Olutosin Awolude
OKOlayinka Adejoke Kotila
Olayinka Adejoke Kotila
OOOladosu Ojengbede
Oladosu Ojengbede
The aim of the descriptive, cross sectional, questionnaire-based study reported here was to explore the causes of low productivity in non-communicable diseases research among postgraduate scholars and early career researchers in Nigeria and identify measures that could facilitate increased research output. The 89 respondents were masters-level, doctoral scholars and resident doctors who attended a workshop. Majorities of the respondents (over 70%) either agreed or strongly agreed that factors contributing to poor non-communicable diseases research productivity include a dearth of in-country researchers with specialized skills, inability of Nigerian researchers to work in multidisciplinary teams, poor funding for health research, sub-optimal infrastructural facilities, and limited use of research findings by policy makers. Almost all the respondents (over 90%) agreed that potential strategies to facilitate non-communicable diseases research output would include increased funding for research, institutionalization of a sustainable, structured capacity building program for early career researchers, establishment of Regional Centers for Research Excellence, and increased use of research evidence to guide government policy actions and programs.

20 May 2022 in JCO Global Oncology
Verified
Journal Article
Open access
PAPrisca Olabisi Adejumo
Prisca Olabisi Adejumo
MOMojisola Morenike Oluwasanu
Mojisola Morenike Oluwasanu
ANAtara Ntekim
Atara Ntekim
OAOlutosin Alaba Awolude
Olutosin Alaba Awolude
OKOlayinka Adejoke Kotila
Olayinka Adejoke Kotila
OOOlufunmilayo I. Olopade
Olufunmilayo I. Olopade
PURPOSE: This study investigated the status of training and preparedness for oncology practice and research and degree of interprofessional collaboration among health care professionals in the six geopolitical regions of Nigeria. METHODS: A convergent parallel mixed methods design was used. Three hundred seventeen respondents completed a three-part, online questionnaire. Self-rated competencies in oncology research (26 items), oncology practice (16 items), and interprofessional collaboration (nine items) were assessed with a one- to five-point Likert scale. Six key informant and 24 in-depth interviews were conducted. Descriptive statistics, analysis of variance, and pairwise t-test were used to analyze the quantitative data, whereas thematic analysis was used for the qualitative data. RESULTS: Respondents were mostly female (65.6%) with a mean age of 40.5 ± 8.3 years. Respondents include 178 nurses (56.2%), 93 medical doctors (29.3%), and 46 pharmacists (14.5%). Self-assessed competencies in oncology practice differed significantly across the three groups of health care professionals ( F = 4.789, P = .009). However, there was no significant difference across professions for competency in oncology research ( F = 1.256, P = .286) and interprofessional collaboration ( F = 1.120, P = .327). The majority of respondents (267, 82.4%) felt that educational opportunities in oncology-associated research in the country are inadequate and that this has implications for practice. Key training gaps reported include poor preparedness in data analysis and bioinformatics (138, 43.5%), writing clinical trials (119, 37.5%), and writing grant/research proposals (105, 33.1%). Challenges contributing to gaps in cancer research include few trained oncology specialists, low funding for research, and inadequate interprofessional collaboration. CONCLUSION: This study highlights gaps in oncology training and practice and an urgent need for interventions to enhance interprofessional training to improve quality of cancer care in Nigeria. These would accelerate progress toward strengthening the health care system and reducing global disparities in cancer outcomes.

1 January 2024 in Cancer Control
Verified
Journal Article
Open access
MOMojisola M Oluwasanu
Mojisola M Oluwasanu
PAPrisca O Adejumo
Prisca O Adejumo
YSYijia Sun
Yijia Sun
COChidera Onwuka
Chidera Onwuka
ANAtara Ntekim
Atara Ntekim
OOOlufunmilayo I Olopade
Olufunmilayo I Olopade
Background: Cancers, with increasing incidence and mortality rates, constitute a leading public health problem in Nigeria. As the burden of cancer in Nigeria increases, research and quality service delivery remain critical strategies for improved cancer control across the continuum of care. This study contextualizes the challenges and gaps in oncology research and practice in Nigeria, and presents recommendations to address the gaps. Methods: This qualitative study was conducted among interprofessional and interdisciplinary stakeholders in oncology healthcare practice and research in academic settings, between July and September 2021. Key-informant interviews were held with six stakeholders and leaders in nursing, pharmacy, and medicine across the six geopolitical zones of Nigeria, and twenty-four in-depth interviews with early- or mid-career researchers or healthcare professionals involved in cancer prevention and treatment were conducted. The data were analyzed using a deductive thematic analysis approach and coded using the NVIVO 12 software. Results: Five sub-themes were identified as major challenges to oncology research, including poor funding, excessive workload, interprofessional rivalry, weak collaboration, and denial of cancer diagnosis by patients. Challenges identified for oncology practice were poor governance and financing, high costs of oncology treatments, poor public awareness of cancer, workforce shortage, and interprofessional conflicts. Recommended strategies for addressing these challenges were improved financing of oncology research and practice by government and relevant stakeholders, increasing interest of medical, nursing, and pharmaceutical students in oncology research through curricula-based approach and mentorship, increased oncology workforce, and improved intra- and inter-professional collaboration. Conclusion: These data highlight the challenges and barriers in oncology practice and research in Nigeria, and underscore the urgent need for increased investments in infrastructure to provide interdisciplinary and interprofessional research training for high-quality care. Only then can Nigeria effectively tackle the current and impending cancer burden in the country.

15 August 2023 in British Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
OKOlayinka Adejoke Kotila
Olayinka Adejoke Kotila
DADavid T. Ajayi
David T. Ajayi
CMCollen Masimirembwa
Collen Masimirembwa
RTRoslyn Thelingwani
Roslyn Thelingwani
AOAbayomi Odetunde
Abayomi Odetunde
CBChinedum P. Babalola
Chinedum P. Babalola

27 February 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
AFAdeshola A. Fagbemi
Adeshola A. Fagbemi
CBChinedum P. Babalola
Chinedum P. Babalola
DKDavid A. Kwasi
David A. Kwasi
OAOlabisi C Akinlabi
Olabisi C Akinlabi
OKOlayinka Adejoke Kotila
Olayinka Adejoke Kotila
IOIruka N. Okeke
Iruka N. Okeke
Background: Biofilms are central to Salmonella pathogenesis, and targeting their formation is believed to produce less evolutionary pressure of growth inhibition than traditional antibacterials. In this study, we screened the Medicines for Malaria Venture (MMV) Pathogen Box library to identify anti-biofilm agents against S . enterica that possess drug-like properties. Methodology/ Principal Findings: A crystal-violet-based medium-throughput antibiofilm screen of Salmonella enterica serovar Typhimurium ATCC 14028 and a clinical Salmonella enterica serovar Elisabethville isolate was performed on polystyrene surfaces using the 400-compound Pathogen Box library. Compounds that inhibited biofilm formation by >30% and growth by <10% were identified as hits. Salmonella red-dry-rough and motility phenotypes were explored in mechanism of action studies on one hit compound. The Salmonella antibiofilm hit rate was 0.75% for this library. MMV688371 (benzamide) inhibited biofilm formation of S . Typhimurium ATCC 14028 by 33% without inhibiting growth. An ethambutol analogue (MMV687273) and auranofin (MMV688978) met the hit criteria against S . Elisabethville LLD035X. Auranofin showed concentration-dependent, growth-inhibition-independent antibiofilm activity against typhoidal and non-typhoidal Salmonella from Nigeria, and inhibited the motility of S . Elisabethville LLD035X at 5 µM. At 5 µM aurothioglucose, an auranofin gold (I) analogue, and non-gold analogue 1-Thio-beta-D-glucose tetraacetate, inhibited biofilm formation by 61.30% and 11.39%, respectively, pointing to essentiality of the gold (I) moiety for activity. Conclusions/ Significance: Structurally diverse small molecules can inhibit biofilm formation by Salmonella, and motility inhibition is an important mechanism for this activity. Auranofin inhibits typhoidal and non-typhoidal Salmonella biofilm formation, with its gold content being required for these activities.

1 May 2026 in JCO Global Oncology
Verified
Journal Article
Open access
ANAtara Ntekim
Atara Ntekim
APAbiodun Popoola
Abiodun Popoola
ASAnthonia Sowunmi
Anthonia Sowunmi
OOOlalekan Olasehinde
Olalekan Olasehinde
ASAyodele Sanni
Ayodele Sanni
OOOlufunmilayo I. Olopade
Olufunmilayo I. Olopade
PURPOSE: Breast cancer is the leading cause of death in Nigerian women. Clinical trials are required to provide evidence for treatment. We aimed to generate efficacy data to support the shift in local practice of neoadjuvant therapy for breast cancer. METHODS: A one-stage, phase II feasibility, single-arm study design was used. Treatment-naïve patients with clinically nonmetastatic human epidermal growth factor receptor 2 (HER2)–positive breast cancer received four cycles of neoadjuvant docetaxel with subcutaneous trastuzumab (T + scH). Patients with complete clinical response underwent surgery. Patients with stable disease/partial response received three further cycles of 5-fluorouracil, epirubicin, and cyclophosphamide + scH before surgery. Responders completed 18 scH cycles. The primary end point was pathologic complete response (pCR). The secondary end points were toxicity and invasive disease-free survival. RESULTS: A total of 53 female patients age 18-70 years were enrolled. The median age of the 47 evaluable female patients was 50 years. pCR was achieved in 25 of 47 patients (53% [95% CI, 38.1 to 67.9]; P < .001). Forty-two percent of patients were estrogen receptor+ and 40% were progesterone receptor+ (95% CI, 20.3 to 66.5 and 21.5 to 69.2, respectively). All were HER2+, with 40% stage II and 60% stage III disease. Three patients (6.4%) experienced grade 3 myelosuppression, one (2.1%) experienced grade 3 diarrhea, two (4.3%) had a grade 4 adverse event, and two developed hepatitis while on the study medications. The reporting of disease-free and overall survival awaits future analysis. CONCLUSION: This phase II study showed that neoadjuvant chemotherapy with T + scH resulted in pCR of 53%, surpassing the planned cutoff for success of 40%. This is comparable with the rates and other efficacy end points that follow data from phase II international trials. This regimen may be useful in the absence of pertuzumab and warrants further investigation.